Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Zinzani, PL; Ramchandren, R; Santoro, A; Paszkiewicz-Kozik, E; Gasiorowski, R; Johnson, NA; de Oliveira, JSR; Buccheri, V; Perini, GF; Dickinson, M; McDonald, A; Ozcan, M; Sekiguchi, N; Zhu, Y; Raut, M; Saretsky, TL; Nahar, A; Kuruvilla, J

Author(s): Zinzani, PL; Ramchandren, R; Santoro, A; Paszkiewicz-Kozik, E; Gasiorowski, R; Johnson, NA; de Oliveira, JSR; Buccheri, V; Perini, GF; Dickinson, M; McDonald, A; Ozcan, M; Sekiguchi, N; Zhu, Y; Raut, M; Saretsky, TL; Nahar, A; Kuruvilla, J;
Details: Publication Year 2022-01-25,Volume 6,Issue #2,Page 590-599
Journal Title: Blood Advances
Publication Type: Research article
Abstract: KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received >/=1 dose of study treatment and completed >/=1 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. Prespecified end points included least squares mean (LSM) changes from baseline to week 24 and time to true deterioration (TTD; >/=10-point decline from baseline). Comparisons were evaluated using 2-sided P values uncontrolled for multiplicity. High compliance at baseline (>90%) and through week 24 (>80%) was demonstrated across treatment groups (PRO analysis set: pembrolizumab, n = 146; BV, n = 150). The EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) score improved from baseline to week 24 on pembrolizumab and worsened on BV and demonstrated significant LSM differences at 24 weeks (GHS/QoL: 8.60 [95% confidence interval, 3.89-13.31]; P = .0004). Significant improvements were observed in each QLQ-C30 domain except emotional and cognitive functioning. Compared with BV, pembrolizumab prolonged TTD for GHS/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) and each QLQ-C30 domain except cognitive functioning. In conclusion, pembrolizumab demonstrated overall improvements in PROs of HRQoL measures over BV in the KEYNOTE-204 study. These data and previously reported efficacy results support pembrolizumab as the preferred treatment option for patients with R/R cHL who are ineligible for or experience relapse after ASCT.
Keywords: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Brentuximab Vedotin; Chronic Disease; *Hematopoietic Stem Cell Transplantation; *Hodgkin Disease/pathology; Humans; Neoplasm Recurrence, Local/drug therapy; Quality of Life; Transplantation, Autologous
Department(s): Haematology
PubMed ID: 34644372
Publisher's Version: https://doi.org/10.1182/bloodadvances.2021004970
Open Access at Publisher's Site: https://doi.org/10.1182/bloodadvances.2021004970
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-16 05:12:24

Last Modified: 2025-05-16 05:13:40